stockrowUnited Therapeutics Corporation
UTHR Healthcare Drug Manufacturers Specialty & Generic
United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024.
- Revenue
- +4.13%
- EPS
- −21.7%
- Free cash flow
- −63.7%
Quarter to September 2026, against a year earlier
Follow UTHR
Alert me
United Therapeutics Corporation (UTHR) Total debt
United Therapeutics Corporation's total debt at the end of fiscal 2024 was $300.0M, down 57.1% from $700.0M in fiscal 2023. At the end of the quarter to 31 March 2025 it was $200.0M. Over the past ten years it has ranged from $250.0M (fiscal 2018) to $850.0M (fiscal 2019); the current reading is higher than 38% of that period. United Therapeutics Corporation ranks 28th of 84 Drug Manufacturers Specialty & Generic companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2024 | $300.0M | (57.14%) |
| FY2023 | $700.0M | (12.50%) |
| FY2022 | $800.0M | 0.00% |
| FY2021 | $800.0M | 0.00% |
| FY2020 | $800.0M | (5.88%) |
| FY2019 | $850.0M | 240.00% |
| FY2018 | $250.0M | 0.00% |
| FY2017 | $250.0M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Mar 2025 | $200.0M | (33.33%) |
| Dec 2024 | $300.0M | (25.00%) |
| Sep 2024 | $400.0M | (20.00%) |
| Jun 2024 | $500.0M | (16.67%) |
| 33 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | $28.8B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $16.7B |
| HLN Haleon PLC Sponsored ADR compare | $11.1B |
| ZTS Zoetis Inc. compare | $9.0B |
| ELAN Elanco Animal Health Incorporated compare | $3.9B |
| VTRS Viatris Inc. compare | $1.7B |
| RDY Dr. Reddy's Laboratories Ltd compare | $753.0M |
| NBIX Neurocrine Biosciences, Inc. compare | $274.0M |
| UTHR United Therapeutics Corporation | $200.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on UTHR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement